Regulatory Perspectives in Pharmacometric Models of Osteoporosis

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of clinical pharmacology

• Publication date

  2018-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jcph.1071PMID 29485684
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bones Structure And Mechanics

  2016cited by this paper
• Postmenopausal osteoporosis

  2016cited by this paper
• A semi-mechanistic model of bone mineral density and bone turnover based on a circular model of bone remodeling

  2015cited by this paper
• FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment?

  2015cited by this paper
• The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine

  2014cited by this paper
• A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis.

  2014cited by this paper
• Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women.

  2014cited by this paper
• Quantification of disease progression and dropout for Alzheimer's disease.

  2013cited by this paper
• The utility of modeling and simulation in drug development and regulatory review.

  2013cited by this paper
• Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.

  2013cited by this paper
• Systems pharmacology to predict drug toxicity: integration across levels of biological organization.

  2013cited by this paper
• An Evaluation of Calcilytic Effects on Parathyroid Hormone and Bone Mineral Density Response Using a Physiologically-Based, Multiscale Systems Pharmacology Model

  2013cited by this paper
• Development of a placebo effect model combined with a dropout model for bipolar disorder

  2013cited by this paper
• Clinical Pharmacology and the Catalysis of Regulatory Science: Opportunities for the Advancement of Drug Development and Evaluation

  2013cited by this paper
• Is This the Dose for You?: The Role of Modeling

  2013cited by this paper
• Application of a mechanism-based disease systems model for osteoporosis to clinical data

  2013cited by this paper
• Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

  2013cited by this paper
• Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey

  2012cited by this paper
• Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease

  2012cited by this paper
• Integrated Pharmacometrics and Systems Pharmacology Model-Based Analyses to Guide GnRH Receptor Modulator Development for Management of Endometriosis

  2012cited by this paper
• Biochemical markers in the follow-up of the osteoporotic patients.

  2012cited by this paper
• Pharmacological Mechanism‐Based Drug Safety Assessment and Prediction

  2011cited by this paper
• Goals of Care for Hip Fracture: Comment on “Hip Fracture and Increased Short-term but Not Long-term Mortality in Healthy Older Women”

  2011cited by this paper
• Coping with time scales in disease systems analysis: application to bone remodeling

  2011cited by this paper
• Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions

  2011cited by this paper
• Bayesian Quantitative Disease–Drug–Trial Models for Parkinson’s Disease to Guide Early Drug Development

  2011cited by this paper
• Goals of care for hip fracture: promoting independence and reducing mortality.

  2011cited by this paper
• Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: a systematic review.

  2011cited by this paper
• Bone Physiology, Disease and Treatment

  2010cited by this paper
• The 1-Year Mortality of Patients Treated in a Hip Fracture Program for Elders

  2010cited by this paper
• Osteonecrosis of the jaw in a patient on Denosumab.

  2010cited by this paper
• A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling.

  2010cited by this paper
• Elucidation of Relationship Between Tumor Size and Survival in Non‐Small‐Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development

  2009cited by this paper
• Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis

  2008cited by this paper
• European guidance for the diagnosis and management of osteoporosis in postmenopausal women

  2008cited by this paper
• European guidance for the diagnosis and management of osteoporosis in postmenopausal women--what is the current message for clinical practice?

  2008cited by this paper
• Model structure and control of bone remodeling: a theoretical study.

  2008cited by this paper
• Disease progression, drug action and Parkinson’s disease: Why time cannot be ignored

  2008cited by this paper
• Bone Remodeling

  2008cited by this paper
• The role of DXA bone density scans in the diagnosis and treatment of osteoporosis

  2007cited by this paper
• Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States, 2005–2025

  2007cited by this paper
• Finite Element Analysis Based on In Vivo HR‐pQCT Images of the Distal Radius Is Associated With Wrist Fracture in Postmenopausal Women

  2007cited by this paper
• The bone mineralization density distribution as a fingerprint of the mineralization process.

  2007cited by this paper
• Long-term proton pump inhibitor therapy and risk of hip fracture.

  2006cited by this paper
• Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.

  2006cited by this paper
• Estrogen deficiency and bone loss: an inflammatory tale.

  2006cited by this paper
• Remodeling

  2006cited by this paper
• A Biomechanical Analysis of the Effects of Resorption Cavities on Cancellous Bone Strength

  2006cited by this paper
• Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis.

  2006cited by this paper
• Osteoporosis and male age-related hypogonadism: role of sex steroids on bone (patho)physiology.

  2006cited by this paper
• Examining the Relationship Between Bone Mineral Density and Fracture Risk Reduction During Pharmacologic Treatment of Osteoporosis

  2006cited by this paper
• An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice

  2006cited by this paper
• Bone Remodeling

  2006cited by this paper
• An estimate of the worldwide prevalence and disability associated with osteoporotic fractures

  2006cited by this paper
• Osteoporosis: trends in epidemiology, pathogenesis and treatment

  2006cited by this paper
• Clinical Practice. Postmenopausal Osteoporosis.

  2005cited by this paper
• Disease System Analysis: Basic Disease Progression Models in Degenerative Disease

  2005cited by this paper
• Response to continuous and pulsatile PTH dosing: a mathematical model for parathyroid hormone receptor kinetics.

  2005cited by this paper
• Biochemical markers of bone turnover: part I: biochemistry and variability.

  2005cited by this paper
• A Novel Mathematical Model Identifies Potential Factors Regulating Bone Apposition

  2005cited by this paper
• Variability of vertebral and femoral postmenopausal bone loss: A longitudinal study

  2005cited by this paper
• Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy.

  2005cited by this paper
• Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.

  2005cited by this paper
• Who are candidates for prevention and treatment for osteoporosis?

  2005cited by this paper
• Can the increase of bone mineral density following bisphosphonates treatments be explained by biomechanical considerations?

  2004cited by this paper
• Modeling the interactions between osteoblast and osteoclast activities in bone remodeling.

  2004cited by this paper
• Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study.

  2004cited by this paper
• A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.

  2004cited by this paper
• Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women.

  2004cited by this paper
• Pathogenesis of osteoporosis.

  2003cited by this paper
• Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation.

  2003cited by this paper
• Proteasomal Degradation of Runx2 Shortens Parathyroid Hormone-induced Anti-apoptotic Signaling in Osteoblasts

  2003cited by this paper
• Bone quality: where do we go from here?

  2003cited by this paper
• Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

  2003cited by this paper
• A Simulation Model at Trabecular Level to Predict Effects of Antiresorptive Treatment after Menopause

  2003cited by this paper
• Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling.

  2003cited by this paper
• A theoretical analysis of the relative influences of peak BMD, age-related bone loss and menopause on the development of osteoporosis

  2003cited by this paper
• Role of the vitamin D‐endocrine system in the pathophysiology of postmenopausal osteoporosis

  2003cited by this paper
• BMD at Multiple Sites and Risk of Fracture of Multiple Types: Long‐Term Results From the Study of Osteoporotic Fractures

  2003cited by this paper
• Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.

  2002cited by this paper
• A minimal mathematical model of calcium homeostasis.

  2002cited by this paper
• Sex steroids and bone.

  2002cited by this paper
• Patients with Hip Fracture: Subgroups and Their Outcomes

  2002cited by this paper
• A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment.

  2001cited by this paper
• Sex steroids and bone.

  2001cited by this paper
• Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up.

  2000cited by this paper
• Bone Sialoprotein is a Specific Biochemical Marker of Bone Metabolism in Postmenopausal Women: A Randomized 1-Year Study

  2000cited by this paper
• Pathogenesis of osteoporosis.

  2000cited by this paper
• Pharmacokinetic/pharmacodynamic modeling in drug development.

  2000cited by this paper
• Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study.

  2000cited by this paper
• Glucocorticoid-induced osteoporosis: pathogenesis and management

  2000cited by this paper
• Fluoride for the Treatment of Postmenopausal Osteoporotic Fractures: A Meta-Analysis

  2000cited by this paper
• Strong Prediction of Fractures Among Older Adults by the Ratio of Carboxylated to Total Serum Osteocalcin

  2000cited by this paper
• Comparison of the European and USA practice guidelines for Osteoporosis.

  2000cited by this paper
• A model of mechanobiologic and metabolic influences on bone adaptation.

  2000cited by this paper
• Biochemical Markers of Bone Turnover, Endogenous Hormones and the Risk of Fractures in Postmenopausal Women: The OFELY Study

  2000cited by this paper
• Clinical Usefulness of Biochemical Resorption Markers in Osteoporosis

  1999cited by this paper
• Predicting bone loss and fracture risk with biochemical markers: A review.

  1999cited by this paper
• Interim Report and Recommendations of the World Health Organization Task-Force for Osteoporosis

  1999cited by this paper
• Book Review: Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis

  1999cited by this paper

• Plasma serotonin precursors and metabolites as diagnostic and therapeutic biomarkers for osteoporosis in postmenopausal women

  2025cites this paper
• Capture the superior anti-osteoporotic innovative multi-component complex from Ligustri Lucidi Fructus based on Component Recombination strategy.

  2025cites this paper
• Using broadly targeted plant metabolomics technology combined with network pharmacology to explore the mechanism of action of the Yishen Gushu formula in the treatment of Postmenopausal osteoporosis in vivo.

  2024cites this paper
• Advances in mechanobiological pharmacokinetic-pharmacodynamic models of osteoporosis treatment - Pathways to optimise and exploit existing therapies.

  2024cites this paper
• Exploring the boost of steaming with wine on Ligustri Lucidi Fructus in treating postmenopausal osteoporosis based on superior "multi-component structure" and iron/bone metabolism coregulation.

  2023cites this paper
• Understanding menopause-postmenopausal complications, management and quality of life

  2021cites this paper
• Nonlinear modeling and control strategies for bone diseases based on TGFβ and Wnt factors

  2021cites this paper
• Serum Pharmacochemistry Analysis Combined with Network Pharmacology Approach to Investigate the Antiosteoporosis Effect of Xianlinggubao Capsule in vivo

  2020cites this paper
• The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis.

  2020cites this paper
• Prediction of Fracture Risk From Early‐Stage Bone Markers in Patients With Osteoporosis Treated With Once‐Yearly Administered Zoledronic Acid

  2020cites this paper
• Establishment of a Disease‐Drug Trial Model for Postmenopausal Osteoporosis: A Zoledronic Acid Case Study

  2020cites this paper
• Pharmacometrics and systems pharmacology for metabolic bone diseases.

  2019cites this paper
• Quantitative Systems Pharmacology models as a key to translational medicine

  2019cites this paper